Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Evans, R. M.
Right arrow Articles by Farlow, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Evans, R. M.
Right arrow Articles by Farlow, M. R.
Related Collections
Right arrow Alzheimer's disease
Right arrow Risk factors in epidemiology
NEUROLOGY 2004;62:1869-1871
© 2004 American Academy of Neurology
Brief Communications

Cholesterol and APOE genotype interact to influence Alzheimer disease progression

R. M. Evans, MD, S. Hui, PhD, A. Perkins, MS, D. K. Lahiri, PhD, J. Poirier, MD and M. R. Farlow, MD

From the Departments of Neurology (Drs. Evans and Farlow), Medicine (Dr. Hui), and Psychiatry (Dr. Lahiri) and Regenstrief Institute for Health Care (Dr. Hui, A. Perkins), Indiana University School of Medicine, Indianapolis; and McGill Centre for Studies in Aging (Dr. Poirier), Montreal, Quebec, Canada.

Address correspondence and reprint requests to Dr. R.M. Evans, Department of Neurology, CL 299, 541 Clinical Dr., Indianapolis, IN 46202; e-mail: revans1{at}iupui.edu

In this retrospective analysis of 443 Alzheimer disease (AD) patients from a 30-week tacrine trial, change in Alzheimer’s Disease Assessment Scale score from baseline to final value was significantly associated with a total serum cholesterol/APOE genotype interaction. Disease progression in the no-APOE {varepsilon}4 allele/high-cholesterol subgroup was greater than in the normal-cholesterol subgroups with or without {varepsilon}4. Cholesterol levels and APOE genotype may interact to affect AD progression. The results are consistent with preclinical data on cholesterol’s effects in AD.

Received September 12, 2003. Accepted in final form January 15, 2004.

Drs. Farlow and Poirier have served as consultants, received honoraria, and conducted clinical trials for Parke Davis (tacrine).




This article has been cited by other articles:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. Singh-Manoux, D. Gimeno, M. Kivimaki, E. Brunner, and M. G. Marmot
Low HDL Cholesterol Is a Risk Factor for Deficit and Decline in Memory in Midlife: The Whitehall II Study
Arterioscler. Thromb. Vasc. Biol., August 1, 2008; 28(8): 1556 - 1562.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. O. W. Grimm, H. S. Grimm, I. Tomic, K. Beyreuther, T. Hartmann, and C. Bergmann
Independent Inhibition of Alzheimer Disease {beta}- and {gamma}-Secretase Cleavage by Lowered Cholesterol Levels
J. Biol. Chem., April 25, 2008; 283(17): 11302 - 11311.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
J. G. Mella, R. Schirin-Sokhan, A. Rigotti, F. Pimentel, L. Villarroel, H. E. Wasmuth, T. Sauerbruch, F. Nervi, F. Lammert, and J. F. Miquel
Genetic evidence that apolipoprotein E4 is not a relevant susceptibility factor for cholelithiasis in two high-risk populations
J. Lipid Res., June 1, 2007; 48(6): 1378 - 1385.
[Abstract] [Full Text] [PDF]

Home page
 J. Gerontol. B Psychol. Sci. Soc. Sci.Home page
C. M. de Frias, D. Bunce, A. Wahlin, R. Adolfsson, K. Sleegers, M. Cruts, C. Van Broeckhoven, and L.-G. Nilsson
Cholesterol and Triglycerides Moderate the Effect of Apolipoprotein E on Memory Functioning in Older Adults
J. Gerontol. B. Psychol. Sci. Soc. Sci., March 1, 2007; 62(2): P112 - P118.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
S. C. Johnson, T. W. Schmitz, M. A. Trivedi, M. L. Ries, B. M. Torgerson, C. M. Carlsson, S. Asthana, B. P. Hermann, and M. A. Sager
The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation.
J. Neurosci., May 31, 2006; 26(22): 6069 - 6076.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. S. Beeri, M. Rapp, J. M. Silverman, J. Schmeidler, H. T. Grossman, J. T. Fallon, D. P. Purohit, D. P. Perl, A. Siddiqui, G. Lesser, et al.
Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers
Neurology, May 9, 2006; 66(9): 1399 - 1404.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
K. Hall, J. Murrell, A. Ogunniyi, M. Deeg, O. Baiyewu, S. Gao, O. Gureje, J. Dickens, R. Evans, V. Smith-Gamble, et al.
Cholesterol, APOE genotype, and Alzheimer disease: An epidemiologic study of Nigerian Yoruba
Neurology, January 24, 2006; 66(2): 223 - 227.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
I Masse, R Bordet, D Deplanque, A Al Khedr, F Richard, C Libersa, and F Pasquier
Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease
J. Neurol. Neurosurg. Psychiatry, December 1, 2005; 76(12): 1624 - 1629.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. J. Nelson and D. L. Alkon
Oxidation of Cholesterol by Amyloid Precursor Protein and {beta}-Amyloid Peptide
J. Biol. Chem., February 25, 2005; 280(8): 7377 - 7387.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.